Figure-1 (Figure 1)
Guanfacine Extended-release Tablet, Extended Release
Product Images NDC 71335-3078
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Guanfacine Extended-release (NDC 71335-3078). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure-2 (Figure 2)
This is a list of medications and their effects on the metabolism enzyme CYP3A4. It includes human data on the inhibitors Ketoconazole and Rifampin, as well as computer simulations of the inhibitors Fluconazole and Efavirenz. The list also mentions the effects on the enzyme by oral Methylphenidate and Lisdexamfetamine Dimesylate. The text refers to changes in the area under the curve (AUC) and fold change percentages. It is evaluating the impact of these medications on CYP3A4.*
Figure-3 (Figure 3)
Figure4.jpg (Figure4)
Label (Lbl713353078)
This is a description of a medication containing 1 mg of Guanfacine as Guanfacine Hydrochloride USP. The tablets should not be crushed, chewed, or broken before swallowing. It should be stored at 20° to 25°C (68° to 77°F) with permitted excursions to 15° to 30°C (59° to 86°F). The usual dosage information can be found by scanning the package insert QR code. The medication is available in a pack of 30 tablets and is manufactured by Apotex Inc. and repackaged by Bryant Ranch Prepack, Inc.*
Spd503-chemical-stucture (Spd503 Chemical Stucture)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
